stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) Total debt
Kodiak Sciences Inc.'s total debt at the end of fiscal 2022 was $178.0M, unchanged from fiscal 2021. At the end of the quarter to 30 September 2023 it was $174.5M. Over the past ten years it has ranged from $103.0K (fiscal 2016) to $178.0M (fiscal 2022) — the current reading is the highest in ten years. Kodiak Sciences Inc. ranks 64th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $178.0M | 1.14% |
| FY2021 | $176.0M | 134.67% |
| FY2020 | $75.0M | 3,650.00% |
| FY2019 | $2.0M | (79.84%) |
| FY2017 | $9.9M | 9,532.04% |
| FY2016 | $103.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $174.5M | (1.40%) |
| Jun 2023 | $176.9M | (1.05%) |
| Mar 2023 | $178.8M | 0.57% |
| Dec 2022 | $177.8M | (0.49%) |
| 17 more quarters | Free account |
Against its own ten years
Low $103.0K
High $178.0M
Ten-year median
$42.5M
Current reading's percentile
100
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| KOD Kodiak Sciences Inc. | $174.5M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt